24小时热门版块排行榜

>论坛更新日志 (3351)
>虫友互识 (795)
>休闲灌水 (117)
>导师招生 (116)
>文献求助 (99)
>博后之家 (96)
>基金申请 (95)
>论文投稿 (89)
>教师之家 (48)
>硕博家园 (44)
>药学 (29)
>考博 (28)
>招聘信息布告栏 (15)
>公派出国 (12)
>考研 (12)
>海外博后 (11)

返回列表

【有奖交流】积极回复本帖子，参与交流，就有机会分得作者 wyb35402641 的 12 个金币，回帖就立即获得 1 个金币，每人有 1 次机会

当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖

wyb35402641

新虫 (小有名气)

应助: 0 (幼儿园)
金币: 392.2
帖子: 76
在线: 62小时
虫号: 229298

[交流] contrast media & molecular imaging 征稿启事

Call for papers
Contrast Media & Molecular Imaging
Molecular Imaging in Targeted Therapeutics
With the rapid development of precision medicine, targeted therapy of tumors has
made great advances. However, tumors of the same type were found to harbor
different molecular alterations such as specific receptor, transporter, cell expression
levels before and even during the targeted therapy. Molecular imaging allows
mapping of disease markers in vivo and disease biology understanding. It promotes
targeted therapy by therapeutic effect prediction, early response evaluation and
therapeutic regimen determination in preclinical and clinical settings. Molecular
imaging technologies are being recognized as the one of most valuable tools in the
field of precision medicine, which will make individual treatment decisions for better
patient outcome care.
The main focus of this special issue will be on the recent advances of molecular
imaging for targeted treatment strategies in precision medicine. We particularly take
an interest in manuscripts that report of targeted therapeutics of molecular imaging for
tumors, but not limited to tumors. This special issue accepts original research articles
as well as review articles that will show a diversity of new developments in these
areas.
Potential topics include but are not limited to the following:
 Molecular imaging guided therapy in targeted chemotherapy, internal
radiotherapy, and precision surgery.
 New advances in molecular imaging for prediction, monitoring, and early
response evaluation of targeted therapy in preclinical and clinical settings.
 Applications in targeted therapy of malignant tumors and benign disease, such as
inflammation/immune disorders, heart and brain disorders (AD, PD).
 Molecular imaging in passive targeted therapy such as chemoembolization,
brachytherapy, drug-encapsulated implant and nanoparticle.
 New target spot such as specific gene, receptor, transporter, antigen and
synthesized targeting probes.
 PET, SPECT, MR, ultrasound, fluorescence, photoacoustic and multimodal
imaging.
Authors can submit their manuscripts through the Manuscript Tracking System at
https://mts.hindawi.com/submit/journals/cmmi/mitt/
Manuscript Due : September 29, 2017
First Round of Reviews: December 22, 2017
Publication Date: February 16, 2018
Lead Guest Editor
Yuebing Wang, Nankai University, Tianjin, China
wangyuebing@ nankai.edu.cn
Guest Editors
Zhen Cheng, Stanford University, Stanford, USA
zcheng@stanford.edu
Shuang Liu, Purdue University, West Lafayette, USA
liu100@purdue.edu
Guoqiang Shao, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
guoqiangshao@163.com
About this Journal
Contrast Media & Molecular Imaging provides an international forum for the
expeditious publication of research articles, reviews, clinical studies, and letters to the
editors in the booming areas of contrast media & molecular imaging.
The most recent Impact Factor for Contrast Media & Molecular Imaging is 3.286
according to the 2015 Journal Citation Reports released by Thomson Reuters in 2016.
The average time between submission and final decision is 47 days and the average
time between acceptance and publication is 34 days.

回复此楼